©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1514-1531
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1514
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1514
Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma
Yong Pan, Yi-Ru Zhang, Ling-Yun Wang, Ying-Qiu Ma, Zhou Fang, Shi-Bo Li, Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, Zhoushan 316021, Zhejiang Province, China
Yi-Ru Zhang, Ling-Yun Wang, State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Li-Na Wu, Department of Infectious Disease, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China
Author contributions: Pan Y and Zhang YR initiated the study and organized it; Wang LY, Ma YQ, and Fang Z designed and carried out bioinformatics analyses, statistical analyses, and drew figures; Pan Y and Wu LN drafted the manuscript; Li SB contributed to the review and editing; all authors have read and agreed to the published version of the manuscript.
Supported by the Zhejiang Province Major Science and Technology Project for Medicine and Health , No. WKJ-ZJ-2329 .
Institutional review board statement: Our research is based on the Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) database and the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) database. All of these are open-access public databases. Thus, no institutional review board approval was required.
Informed consent statement: Patients were not required to give informed consent to the study because our research is based on the databases.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Corresponding author: Shi-Bo Li, Doctor, Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, No. 739 Dingshen Road, Zhoushan 316021, Zhejiang Province, China. lsb0398@126.com
Received: November 24, 2023
Peer-review started: November 24, 2023
First decision: January 12, 2024
Revised: January 16, 2024
Accepted: February 4, 2024
Article in press: February 4, 2024
Published online: April 15, 2024
Processing time: 138 Days and 11 Hours
Peer-review started: November 24, 2023
First decision: January 12, 2024
Revised: January 16, 2024
Accepted: February 4, 2024
Article in press: February 4, 2024
Published online: April 15, 2024
Processing time: 138 Days and 11 Hours
Core Tip
Core Tip: In this study, the mutation landscape, and molecular biological mechanisms of cyclin dependent kinase inhibitor 2A (CDKN2A) in hepatocellular carcinoma (HCC) was first explored, and a CDKN2A-related competitive endogenous RNA axis was constructed. We identified growth arrest specific 5 as an independent prognostic biomarker and established a prognostic nomogram model for HCC. Moreover, we analyzed its methylation level, immune infiltration, and targeted agents, which might be an independent prognostic biomarker and therapeutic target in HCC.